# Multimodal Biomarkers for Diagnosis and Prognosis in CAA

> **NCT03969732** · PHASE3 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Cerebral Amyloid Angiopathy
- Intracranial Hemorrhages
- Alzheimer Disease

## Interventions

- **DRUG:** 1. amyloid PET；2. T807 PET

## Key facts

- **NCT ID:** NCT03969732
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-27
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2021-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969732, "Multimodal Biomarkers for Diagnosis and Prognosis in CAA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03969732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*